Skip Nav Destination
Issues
1 November 2004
- Cover Image
- PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Issue Sections
The Biology Behind
Featured Articles
Clinical Trials
Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule: A Phase I Pharmacokinetic and Food Effect Study
Emiliano Calvo; Anthony W. Tolcher; Lisa A. Hammond; Amita Patnaik; Johan S. de Bono; Irene A. Eiseman; Stephen C. Olson; Peter F. Lenehan; Heather McCreery; Patricia LoRusso; Eric K. Rowinsky
A Phase I Open Label Study of the Farnesyltransferase Inhibitor CP-609,754 in Patients with Advanced Malignant Tumors
Stacy L. Moulder; John J. Mahany; Richard Lush; Caio Rocha-Lima; Michael Langevin; Karen J. Ferrante; Lisa Michele Bartkowski; Shama M. Kajiji; Dennis A. Noe; Simone Paillet; Daniel M. Sullivan
Phase II Feasibility and Pharmacokinetic Study of Concurrent Administration of Trastuzumab and High-Dose Chemotherapy in Advanced HER2+ Breast Cancer
Yago Nieto; James J. Vredenburgh; Elizabeth J. Shpall; Scott I. Bearman; Peter A. McSweeney; Nelson Chao; David Rizzieri; Christina Gasparetto; Steve Matthes; Anna E. Barón; Roy B. Jones
Molecular Oncology, Markers, Clinical Correlates
Correlation of Molecular Genetics with Molecular and Morphological Imaging in Gliomas with an Oligodendroglial Component
Carol Walker; Daniel G. du Plessis; Diane Fildes; Brian Haylock; David Husband; Michael D. Jenkinson; Kathy A. Joyce; John Broome; Klaus Kopitski; Joanne Prosser; Trevor Smith; Sobhan Vinjamuri; Peter C. Warnke
Experimental Therapeutics, Preclinical Pharmacology
In vitro Stimulation with WT1 Peptide-Loaded Epstein-Barr Virus-Positive B Cells Elicits High Frequencies of WT1 Peptide-Specific T Cells with In vitro and In vivo Tumoricidal Activity
Ekaterina S. Doubrovina; Mikhail M. Doubrovin; Sangyull Lee; Jae-Hung Shieh; Glen Heller; Eric Pamer; Richard J. O’Reilly
Regular Articles
Clinical Trials
Phase I Study of Docetaxel in Combination with the P-Glycoprotein Inhibitor, Zosuquidar, in Resistant Malignancies
Paula M. Fracasso; Lori J. Goldstein; Dinesh P. de Alwis; Janet S. Rader; Matthew A. Arquette; Sherry A. Goodner; Lisa P. Wright; Carole L. Fears; Robert J. Gazak; Valerie A. M. Andre; Michael F. Burgess; Christopher A. Slapak; Jan H. M. Schellens
A Phase I and Pharmacokinetic Study of Exisulind and Docetaxel in Patients with Advanced Solid Tumors
Samir E. Witta; Daniel L. Gustafson; A. Scott Pierson; Alexander Menter; Scott N. Holden; Michele Basche; Martha Persky; Cindy L. O’Bryant; Chan Zeng; Anna Baron; Michael E. Long; Amy Gibbs; Karen Kelly; Paul A. Bunn, Jr.; Daniel C. Chan; Patrick Pallansch; S. Gail Eckhardt
Delivery of a Liposomal c-raf-1 Antisense Oligonucleotide by Weekly Bolus Dosing in Patients with Advanced Solid Tumors: A Phase I Study
Charles M. Rudin; John L. Marshall; Chao Hui Huang; Hedy L. Kindler; Chuanbo Zhang; Deepak Kumar; Prafulla C. Gokhale; Joyce Steinberg; Steve Wanaski; Usha N. Kasid; Mark J. Ratain
Cancer Biology, Immunology, Cytokines
Research Articles
Molecular Oncology, Markers, Clinical Correlates
Increased Levels of Interleukin-10 in Serum from Patients with Hepatocellular Carcinoma Correlate with Profound Numerical Deficiencies and Immature Phenotype of Circulating Dendritic Cell Subsets
Susanne Beckebaum; Xia Zhang; Xiao Chen; Zhengya Yu; Andrea Frilling; Grzegorz Dworacki; Hans Grosse-Wilde; Christoph Erich Broelsch; Guido Gerken; Vito R. Cicinnati
Experimental Therapeutics, Preclinical Pharmacology
Advertisement